Successful ethinylestradio therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies.
Successful ethinylestradio therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies.
复制标题
对经过内分泌治疗的转移性乳腺癌患者进行了成功的炔雌醇疗法。
DOI：
10.1007/s13691-015-0241-7
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Iwase H.
中科院分区：
文献类型：
--
作者：
Sueta A;Hayashi M;Fukugawa Y;Shimizu H;Yamamoto-Ibusuki M;Yamamoto Y;Iwase H.
转移性乳腺癌内分泌治疗成功的关键策略是延长治疗时间。在这里，我们报告了一个晚期转移性乳腺癌的病例，她对大剂量雌激素治疗有显着的反应，疾病长期稳定。一名52岁女性转移性乳腺癌被转介到我们医院。她已经接受了几个疗程的全身治疗：LH-RH激动剂和他莫昔芬和多西他赛。在第一次访问我们，她有一个多发性肝肿瘤和不规则的肿块在左乳房。我们开始内分泌治疗的LH-RH激动剂和阿那曲唑与稳定的疾病12个月。疾病进展后，给予LH-RH激动剂和来曲唑、TS-1、长春瑞滨和白蛋白结合型紫杉醇。此外，她接受了西美坦治疗作为第五线，但4个月后疾病进展。然后我们开始了乙炔雌二醇（EE 2）治疗。2个月后，肝内肿瘤由15.8 cm迅速缩小至10.6 cm，缩小率为33%。随后，患者病情稳定12个月。EE 2治疗14个月后，患者肝肿瘤再生长，然后再次接受来曲唑治疗。此治疗持续了5个月。雌激素治疗对绝经后患者有益，这些患者可能对芳香化酶抑制剂产生耐药性。
The critical strategy leading to the success of endocrine therapy in metastatic breast cancer is ex tended duration of treatment. Here, we report a case with late-stage metastatic breast cancer who dramatically responded to high-dose estrogen treatment with a long-term stable disease. A 52-year-old female with metastatic breast cancer was referred to our hospital. She had already received several courses of systemic therapy: LH-RH agonist and tamoxifen and docetaxel. At first visit to us, she had a multiple liver tumor and an irregular mass in the left breast. We started endocrine therapy of LH-RH agonist and anastrozole with a stable disease for 12 months. After the disease progression, LH-RH agonist and letrozole, TS-1, vinorelubine, and nab-paclitaxel were administered. Further, she received the exemestane therapy as the fifth line, but the disease progressed after 4 months. We then started ethinylestradiol (EE2) therapy. Two months later, the tumor in liver rapidly decreased from 15.8 to 10.6 cm, of which the tumor shrinkage rate was 33 %. Subsequently, the patient had stable disease for 12 months. After 14-month EE2 therapy, the patient had a regrowth of the liver tumors, and was then treated with letrozole again. This therapy had continued for 5 months. Estrogen therapy is beneficial for postmenopausal patients with heavily pre-treated who could have acquired resistance to aromatase inhibitor.